S
IART icon

Sachetta’s Integra LifeSciences IART Stock Holding History

Sachetta’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-46
Closed -$1.15K – 1256
2024
Q2 		$1.15K Buy
+46
New +$1.36K ﹤0.01% 1017

Other funds holding IART

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Sachetta's IART Position: Q3 2024 in Review

Sachetta sold out of Integra LifeSciences (IART) in Q3 2024, closing a stake of 46 shares — an estimated $1.15K sold.

Sachetta first reported a position in IART in Q2 2024 and held it in 1 quarter. The position peaked at $1.15K in Q2 2024. 225 funds tracked by Wall St. Rank hold IART as of Q3 2024.

  • Sachetta reported no remaining Integra LifeSciences position as of Q3 2024 after selling out during the quarter.
  • Sachetta sold 46 Integra LifeSciences shares in Q3 2024, an estimated $1.15K.
  • Sachetta first reported a position in Integra LifeSciences in Q2 2024 and held it in 1 quarter.
  • Sachetta's Integra LifeSciences position peaked at $1.15K in Q2 2024.
  • 225 funds tracked by Wall St. Rank held Integra LifeSciences as of Q3 2024.

Based on Sachetta's 13F filing for Q3 2024, filed 8 Nov 2024.